Related Experiment Video
Updated: Jul 29, 2025

In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge
Published on: June 15, 2018
CORM-A1 Alleviates Pro-Atherogenic Manifestations via miR-34a-5p Downregulation and an Improved Mitochondrial
Hitarthi S Vyas1, Ravirajsinh N Jadeja2, Aliasgar Vohra1
1Chronobiology and Metabolic Endocrinology Lab, Department of Zoology, Faculty of Science, The Maharaja Sayajirao University of Baroda, Vadodara 390002, India.
Abstract:
Atherogenesis involves multiple cell types undergoing robust metabolic processes resulting in mitochondrial dysfunction, elevated reactive oxygen species (ROS), and consequent oxidative stress. Carbon monoxide (CO) has been recently explored for its anti-atherogenic potency; however, the effects of CO on ROS generation and mitochondrial dysfunction in atherosclerosis remain unexplored. Herein, we describe the anti-atherogenic efficacy of CORM-A1, a CO donor, in in vitro (ox-LDL-treated HUVEC and MDMs) and in vivo (atherogenic diet-fed SD rats) experimental models. In agreement with previous data, we observed elevated miR-34a-5p levels in all our atherogenic model systems. Administration of CO via CORM-A1 accounted for positive alterations in the expression of miR-34a-5p and transcription factors/inhibitors (P53, NF-κB, ZEB1, SNAI1, and STAT3) and DNA methylation pattern, thereby lowering its countenance in atherogenic milieu. Inhibition of miR-34a-5p expression resulted in restoration of SIRT-1 levels and of mitochondrial biogenesis. CORM-A1 supplementation further accounted for improvement in cellular and mitochondrial antioxidant capacity and subsequent reduction in ROS. Further and most importantly, CORM-A1 restored cellular energetics by improving overall cellular respiration in HUVECs, as evidenced by restored OCR and ECAR rates, whereas a shift from non-mitochondrial to mitochondrial respiration was observed in atherogenic MDMs, evidenced by unaltered glycolytic respiration and maximizing OCR. In agreement with these results, CORM-A1 treatment also accounted for elevated ATP production in both in vivo and in vitro experimental models. Cumulatively, our studies demonstrate for the first time the mechanism of CORM-A1-mediated amelioration of pro-atherogenic manifestations through inhibition of miR-34a-5p expression in the atherogenic milieu and consequential rescue of SIRT1-mediated mitochondrial biogenesis and respiration.
Insights
Carbon monoxide (CO) from CORM-A1 donor reduces oxidative stress and mitochondrial dysfunction in atherosclerosis. This CO therapy inhibits miR-34a-5p, restoring mitochondrial function and energetics, offering a novel therapeutic approach.
Area of Science:
- Cardiovascular Biology
- Mitochondrial Medicine
- Oxidative Stress Research
Background:
- Atherogenesis involves cellular metabolic dysfunction, increased reactive oxygen species (ROS), and oxidative stress.
- The role of carbon monoxide (CO) in mitigating these atherosclerotic processes, particularly concerning ROS and mitochondrial health, remains largely unexplored.
Purpose of the Study:
- To investigate the anti-atherogenic effects of CORM-A1, a CO-releasing molecule, in vitro and in vivo.
- To elucidate the underlying mechanisms, focusing on microRNA-34a-5p (miR-34a-5p) regulation and mitochondrial function.
Main Methods:
- Utilized in vitro models (ox-LDL-treated HUVECs and MDMs) and an in vivo model (atherogenic diet-fed SD rats).
- Assessed the impact of CORM-A1 on miR-34a-5p expression, transcription factors (P53, NF-κB, ZEB1, SNAI1, STAT3), DNA methylation, mitochondrial biogenesis, ROS levels, cellular respiration (OCR, ECAR), and ATP production.
Main Results:
- CORM-A1 administration normalized elevated miR-34a-5p levels in atherogenic models.
- CO treatment via CORM-A1 restored SIRT-1 levels, promoted mitochondrial biogenesis, enhanced antioxidant capacity, and reduced ROS.
- CORM-A1 improved cellular energetics, restoring respiration and increasing ATP production in both in vitro and in vivo systems.
Conclusions:
- CORM-A1 demonstrates significant anti-atherogenic efficacy by inhibiting miR-34a-5p expression.
- This mechanism rescues SIRT1-mediated mitochondrial biogenesis and function, ameliorating pro-atherogenic conditions.
- CO therapy presents a promising strategy for treating atherosclerosis by targeting mitochondrial dysfunction and oxidative stress.
More Related Videos
Related Concept Videos
Lipid Catabolism
Mitochondria
Atherosclerosis III: Management
MicroRNAs
Mitochondrial Precursor Proteins
Most of the mitochondrial...
Cholesterol: Significance and Regulation
Considering cholesterol and...

